Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 04/02/25
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksCNBC • 04/01/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing ApprovalSeeking Alpha • 03/23/25
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention FundingInvestors Business Daily • 03/19/25
Buy 3 U.S. Giants Flying High Year to Date Defying Severe VolatilityZacks Investment Research • 03/19/25
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention FundingBarrons • 03/19/25
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?Zacks Investment Research • 03/17/25
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025Zacks Investment Research • 03/13/25
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy OptionBusiness Wire • 03/12/25
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)Seeking Alpha • 03/11/25
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The LancetBusiness Wire • 03/11/25
Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent BloodbathZacks Investment Research • 03/11/25